ClinicalTrials.gg
CompletedNCT05532800Updated Mar 15, 2023

The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia

A Phase 3 interventional study of JS002 and Placebo in Hyperlipemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Completed at 21 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Feb 2022, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Hyperlipidemias with a site in China — 31 open to participants now, 39 under way, 7 of them phase 3. Hyperlipidemias · China.

Enrollment
25th of 80
255 · median 155
Started
2022
with 8 others
Phase 3
20 of 96
4 open now
Registered
44th of 96
by date
Lead sponsor
5 of 96
Shanghai Junshi Bioscience Co., Ltd.

Among the 96 studies in Hyperlipidemias with a site in China, this one is the 25th largest by enrollment of the 80 interventional ones that give a count, is one of 9 that started in 2022, is one of 20 in phase 3, and was the 44th registered.

Hyperlipidemias

864 studies on the registry are indexed under Hyperlipidemias; 110 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

31 of the 96 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Hyperlipidemias with a site in China, or all of them as a file.
02

Study summary

JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody. This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of JS002 prefilled syringes and prefilled autosyringes in patients with primary hypercholesterolemia and mixed hyperlipidemia when combined with statin therapy.

In this study, one dose group (150 mg) were set up in this study. 240 subjects are plan to be enrolled (the study drug will be assigned to a 2:1 :2:1ratio of JS002 PFS / placebo or JS002 AI / placebo ).

Each subject required a maximum of 6 weeks of screening, 12 weeks of treatment, and 8 weeks of follow-up.

03

Conditions studied

  • Hyperlipemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Age 18\~80 years old;
  3. Stable optimized LLT at least 4 weeks before randomization;
  4. Two times of Fasting triglycerides ≤4.5 mmol/L(400mg/dL)at the time of screening;

Exclusion criteria

Exclusion Criteria:

  1. History of class III-IV heart failure or EF\<30%;
  2. History of uncontrolled arrhythmia within 90 days;
  3. History of MI,UA, PCI or CABG, stroke within 90 days;
  4. Known hemorrhagic stroke disease;
  5. Planned cardiac surgery or revascularization.
  6. Uncontrolled hypertension.
  7. Uncontrolled diabetes mellitius (>8.0%).
  8. Other conditions that the researchers considered inappropriate to participate in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    JS002

    Cobort 1:150 mg/1mL Q2W PFS,Cobort 2:150 mg/1mL Q2W AI

    Drug: JS002

  • Placebo comparator
    Placebo

    Cobort 1:/1mL Q2W PFS,Cobort 2:1mL Q2W AI

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. LDL-C with JS002 PFS

    Percentage change in LDL-C relative to baseline at Week 12 with JS002 PFS

    Time frame: at week 12

  2. LDL-C with JS002 AI

    Percentage change in LDL-C relative to baseline at Week 12 with JS002 AI

    Time frame: at week 12

Secondary outcomes

  1. LDL-C with JS002 PFS

    The absolute change in LDL-C relative to baseline with JS002 PFS

    Time frame: at week 12

  2. LDL-C with JS002 AI

    The absolute change in LDL-C relative to baseline with JS002 AI

    Time frame: at week 12

  3. lipid parameters

    Percentages and absolute change in other lipid parameters to baseline with JS002 PFS and JS002 AI

    Time frame: at week 12

  4. LDL-C reduction≥50 with JS002 PFS

    Proportion of subjects with a ≥50% reduction in serum LDL-C at 12 weeks after subcutaneous treatment with JS002 PFS from baseline

    Time frame: at week 12

  5. LDL-C reduction≥50 with JS002 AI

    Proportion of subjects with a ≥50% reduction in serum LDL-C at 12 weeks after subcutaneous treatment with JS002 AI from baseline

    Time frame: at week 12

  6. LDL-C dropped to < 70 mg/dL with JS002 PFS

    Proportion of subjects whose serum LDL-C dropped to \< 70 mg/dL (1.8 mmol/L) at 12 weeks after subcutaneous injection of JS002 PFS

    Time frame: at week 12

  7. LDL-C dropped to < 70 mg/dL with JS002 AI

    Proportion of subjects whose serum LDL-C dropped to \< 70 mg/dL (1.8 mmol/L) at 12 weeks after subcutaneous injection of JS002 AI

    Time frame: at week 12

  8. full dose

    Proportion of subjects receiving full dose of JS002 AI during treatment (weeks 0, 2, 4, 6, 8, 10)

    Time frame: at week 0, 2, 4, 6, 8, 10

07

Study locations

21 sites
  • Beijing Anzhen Hospital,Capital Medical University
    Beijing, Beijing 100029, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • China-Japan Friendship Hospital
    Beijing, Beijing 100192, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • Daqing People's Hospital
    Daqing, Heilongjiang 163711, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
  • The Second Xiangya Hospital Of Central South University
    Changsha, Hunan 410008, China
  • Changzhou Second People's Hospital
    Changzhou, Jiangsu 213004, China
  • Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221004, China
  • Nanchang First Hospital
    Nanchang, Jiangxi 330008, China
  • Nanchang Third Hospital
    Nanchang, Jiangxi 330008, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330008, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130061, China
  • Dalian Municipal Central Hospital
    Dalian, Liaoning 116089, China
  • The First Affiliated Hospital of Jinzhou Medical University
    Jinzhou, Liaoning 121011, China
  • Xianyang Hospital of Yan'an University
    Xianyang, Shanxi 716099, China
  • Tianjin People's Hospital
    Tianjin, Tianjin 300122, China
  • Taizhou Hospital Of Zhejiang Province
    Taizhou, Zhejiang 317000, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325015, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Feb 2023, 11 months.

Of 57 phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 32. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2022
First posted
Sep 8, 2022
StartActual
Feb 28, 2022
Primary completionActual
Feb 9, 2023
CompletionActual
Feb 9, 2023
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05532800
Responsible party
Sponsor
First posted
Sep 8, 2022
Start date
Feb 28, 2022
Primary completion
Feb 9, 2023
Completion
Feb 9, 2023
Last update
Mar 15, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ongericimab

Start the discussion